Blog
RSS FeedPosted by Michael Wonder on 21 Dec 2023
Ravulizumab for the treatment of patients with AQP4 antibody positive neuromyelitis optica spectrum disorder
20 December 2023 - NICE is unable to make a recommendation on the use of ravulizumab (Ultomiris) for the treatment of ...
Posted by Michael Wonder on 20 Dec 2023
Empagliflozin for the treatment of patients with chronic kidney disease
20 December 2023 - NICE has published evidence-based recommendations on the use of empagliflozin (Jardiance) for the treatment of adults ...
Posted by Michael Wonder on 20 Dec 2023
Budesonide for the treating primary IgA nephropathy
20 December 2023 - NICE has published evidence-based recommendations on the use of budesonide (Kinpeygo) for the treatment of adults ...
Posted by Michael Wonder on 20 Dec 2023
Ravulizumab for the treatment of patients with generalised myasthenia gravis
20 December 2023 - NICE is unable to make a recommendation on the use of ravulizumab (Ultomiris) for the treatment of ...
Posted by Michael Wonder on 13 Dec 2023
Velmanase alfa for the treatment of patients with alfa mannosidosis
13 December 2023 - NICE has published final evidence-based recommendations on the use of velmanase alfa (Lamzede) for treatment of ...
Posted by Michael Wonder on 13 Dec 2023
Pembrolizumab and chemotherapy with or without bevacizumab for patients with persistent, recurrent or metastatic cervical cancer
13 December 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) and chemotherapy with or ...
Posted by Michael Wonder on 12 Dec 2023
Efgartigimod for the treatment of patients with generalised myasthenia gravis (draft guidance 2)
12 December 2023 - NICE has published further draft guidance on the use of efgartigimod for the treatment of patients ...
Posted by Michael Wonder on 07 Dec 2023
Dupilumab for the treatment of patients with eosinophilic oesophagitis
7 December 2023 - NICE is unable to make a recommendation on the use of dupilumab (Dupixent) for the treatment of ...
Posted by Michael Wonder on 06 Dec 2023
Secukinumab for the treatment of patients with moderate to severe hidradenitis suppurativa (final guidance)
6 December 2023 - NICE has published final evidence-based recommendations on the use of secukinumab (Cosentyx) for the treatment of ...
Posted by Michael Wonder on 05 Dec 2023
Government sends mixed message to global life science investors
5 December 2023 - The Government has published new terms for the Statutory Scheme for branded medicines, maintaining sales rebates ...
Posted by Michael Wonder on 01 Dec 2023
Pembrolizumab with trastuzumab and chemotherapy for the first-line treatment of patients with advanced HER2 positive gastric or gastro-oesophageal junction cancer
1 December 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Nov 2023
Burosumab for the treatment of adults with X-linked hypophosphataemia
29 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Nov 2023
Cabozantinib maleate with nivolumab for patients with untreated advanced renal cell carcinoma
30 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Nov 2023
Idecabtagene vicleucel for the treatment of patients with relapsed and refractory multiple myeloma after 3 or more treatments
30 November 2023 - NICE is unable to make a recommendation on the use of idecabtagene vicleucel (Abecma) for the treatment ...
Posted by Michael Wonder on 29 Nov 2023
Belzutifan for the treatment of patients with a tumour associated with von Hippel-Lindau disease
29 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...